| pubmed-article:2256740 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2256740 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2256740 | lifeskim:mentions | umls-concept:C0013072 | lld:lifeskim |
| pubmed-article:2256740 | lifeskim:mentions | umls-concept:C0011644 | lld:lifeskim |
| pubmed-article:2256740 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:2256740 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:2256740 | lifeskim:mentions | umls-concept:C1696465 | lld:lifeskim |
| pubmed-article:2256740 | lifeskim:mentions | umls-concept:C0681804 | lld:lifeskim |
| pubmed-article:2256740 | lifeskim:mentions | umls-concept:C1512888 | lld:lifeskim |
| pubmed-article:2256740 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:2256740 | pubmed:dateCreated | 1991-1-22 | lld:pubmed |
| pubmed-article:2256740 | pubmed:abstractText | A six month controlled study of 5-fluorouracil in the treatment of scleroderma showed a modest benefit in skin scores, Raynaud's phenomenon, and patients' global assessment. Visceral organ and hand function were unaffected. Mild to moderate toxicity was common in the 5-fluorouracil treated patients but usually responded to dose reduction. Two patients receiving 5-fluorouracil died from causes seemingly unrelated to treatment. Significant clinical improvement in scleroderma was not noted in the first six months of treatment with 5-fluorouracil. | lld:pubmed |
| pubmed-article:2256740 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2256740 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2256740 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2256740 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2256740 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:2256740 | pubmed:issn | 0003-4967 | lld:pubmed |
| pubmed-article:2256740 | pubmed:author | pubmed-author:BlackburnW... | lld:pubmed |
| pubmed-article:2256740 | pubmed:author | pubmed-author:NolteCC | lld:pubmed |
| pubmed-article:2256740 | pubmed:author | pubmed-author:AlarcónG SGS | lld:pubmed |
| pubmed-article:2256740 | pubmed:author | pubmed-author:CasasJ AJA | lld:pubmed |
| pubmed-article:2256740 | pubmed:author | pubmed-author:SawayP APA | lld:pubmed |
| pubmed-article:2256740 | pubmed:author | pubmed-author:SubausteC PCP | lld:pubmed |
| pubmed-article:2256740 | pubmed:author | pubmed-author:VillarrealII | lld:pubmed |
| pubmed-article:2256740 | pubmed:author | pubmed-author:MenajovskyB... | lld:pubmed |
| pubmed-article:2256740 | pubmed:author | pubmed-author:EscuderoE EEE | lld:pubmed |
| pubmed-article:2256740 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2256740 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:2256740 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2256740 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2256740 | pubmed:pagination | 926-8 | lld:pubmed |
| pubmed-article:2256740 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:2256740 | pubmed:meshHeading | pubmed-meshheading:2256740-... | lld:pubmed |
| pubmed-article:2256740 | pubmed:meshHeading | pubmed-meshheading:2256740-... | lld:pubmed |
| pubmed-article:2256740 | pubmed:meshHeading | pubmed-meshheading:2256740-... | lld:pubmed |
| pubmed-article:2256740 | pubmed:meshHeading | pubmed-meshheading:2256740-... | lld:pubmed |
| pubmed-article:2256740 | pubmed:meshHeading | pubmed-meshheading:2256740-... | lld:pubmed |
| pubmed-article:2256740 | pubmed:meshHeading | pubmed-meshheading:2256740-... | lld:pubmed |
| pubmed-article:2256740 | pubmed:meshHeading | pubmed-meshheading:2256740-... | lld:pubmed |
| pubmed-article:2256740 | pubmed:meshHeading | pubmed-meshheading:2256740-... | lld:pubmed |
| pubmed-article:2256740 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2256740 | pubmed:articleTitle | 5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study. | lld:pubmed |
| pubmed-article:2256740 | pubmed:affiliation | Department of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru. | lld:pubmed |
| pubmed-article:2256740 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2256740 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2256740 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2256740 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:2256740 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2256740 | lld:pubmed |
